Detalhe da pesquisa
1.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084760
2.
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.
Blood
; 143(7): 597-603, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048552
3.
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Blood
; 142(18): 1518-1528, 2023 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37506339
4.
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study.
Haematologica
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38356463
5.
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 24(7): e293-e311, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414019
6.
Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
Br J Haematol
; 200(2): 187-196, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36210485
7.
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Blood
; 137(1): 49-60, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32693406
8.
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Haematologica
; 108(11): 2894-2912, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37608773
9.
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.
Haematologica
; 108(10): 2753-2763, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37102598
10.
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Haematologica
; 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031761
11.
Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period.
Br J Haematol
; 196(3): 649-659, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34622447
12.
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
Br J Haematol
; 196(3): 639-648, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34671975
13.
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.
Blood
; 135(26): 2375-2387, 2020 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32299093
14.
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma.
Blood
; 136(2): 199-209, 2020 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32325491
15.
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Haematologica
; 107(10): 2408-2417, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35354247
16.
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma.
Am J Hematol
; 97(6): 700-710, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35188691
17.
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
Lancet Oncol
; 22(1): 142-154, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33301738
18.
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 22(3): e105-e118, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33662288
19.
Complement as the enabler of carfilzomib-induced thrombotic microangiopathy.
Br J Haematol
; 193(1): 181-187, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469083
20.
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.
Br J Haematol
; 192(3): 522-530, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32501528